Relationship Between Severity of Adverse Events of Afatinib and Its Pharmacokinetics and Pharmacogenomics for EGFR Mutation-Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Gomyo, T. [1 ]
Iihara, H. [2 ]
Hayashi, H. [3 ]
Endo, J. [1 ]
Ito, F. [1 ]
Yansase, K. [1 ]
Kaito, D. [1 ]
Sasaki, Y. [1 ]
Sakai, C. [1 ]
Fukuda, Y. [3 ]
Hirose, C. [2 ]
Sugiyama, T. [1 ]
Suzuki, A. [2 ]
Ohno, Y. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Gifu, Japan
[2] Gifu Univ Hosp, Gifu, Japan
[3] Gifu Pharmaceut Univ, Gifu, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3936
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
    Tanaka, Satomi
    Uchino, Junji
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S369 - S372
  • [22] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [23] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 83 - 84
  • [24] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    LUNG CANCER, 2015, 88 (01) : 74 - 79
  • [25] Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinib
    Yang, J. Chih-Hsin
    Sequist, L.
    O'Byrne, K.
    Schuler, M.
    Mok, T.
    Geater, S.
    Massey, D.
    O'Brien, D.
    Zazulina, V.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S190 - S190
  • [26] Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
    Bennouna, Jaafar
    FUTURE ONCOLOGY, 2017, 13 (21) : 1829 - 1833
  • [27] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [28] Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer
    Huh, Ki Young
    Lim, Yeji
    Yoon, Deok Yong
    Hwang, Jun Gi
    Sim, Sujin
    Kang, Jiah
    Wang, Jangyoung
    Kim, Mikyung
    Jang, Seong Bok
    Shreeve, S. Martin
    Mehta, Jaydeep
    Haddish-Berhane, Nahor
    Oh, Jaeseong
    Lee, Seunghwan
    Yu, Kyung-Sang
    LUNG CANCER, 2023, 175 : 112 - 120
  • [29] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [30] Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer
    Zenke, Yoshitaka
    Umemura, Shigeki
    Sugiyama, Eri
    Kirita, Keisuke
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Ohmatsu, Hironobu
    Goto, Koichi
    LUNG CANCER, 2016, 99 : 1 - 3
12345